Fig. 6

The process of counter-immunoediting therapy. Patients are first phenotyped from the initial diagnosis to understand their immune status, followed by the selection of appropriate normalized treatment strategies according to different phenotypes; When the escape phase retrogrades to the equilibrium or elimination phase, the corresponding treatment strategy is selected for further intervention to help the immune system effectively target and kill tumor cells. This approach has the potential to enable patients to achieve a CR or maintain a long-term cure by taking into account the patient's unique immune phenotypes and selecting the most appropriate treatment strategy. RTK Receptor tyrosine kinase inhibitors, TME Tumor microenvironment